Gosset Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Zenopharm General Information
Zenopharm is advancing ZB716, an oral selective estrogen receptor degrader designed to improve bioavailability over existing therapies like fulvestrant. Preclinical data show superior pharmacokinetics and efficacy in breast tumor models. The company has received SBIR funding to complete IND-enabling studies and has initiated a Phase I clinical trial supported by a $4 million investment. Their portfolio also includes boron-based prodrugs targeting breast cancer and novel agents inhibiting tumor angiogenesis[1][2][5][8].
Contact Information
Primary Industry
Biotech
Corporate Office
New Orleans, Louisiana
United States
United States
Drug Pipeline
borestrant
Pre-clinicalKey Partnerships
Avista Pharma Solutions for GMP manufacturing of API[5], Covance for nonclinical development plan implementation[5], Collaboration with Xavier University researchers at founding[1]
Zenopharm Funding
No funding data available
To view Zenopharm's complete valuation and funding history, request access »